Related Experiment Video

Updated: May 30, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

775

Multifaceted roles of insulin‑like growth factor 2 mRNA binding protein 2 in human cancer (Review)

Jianan Shen1, Youxiang Ding1

  • 1Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, P.R. China.

Molecular Medicine Reports
|January 31, 2025
PubMed

Insights

Insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) is a key regulator in human cancers, affecting RNA stability and expression. Targeting IGF2BP2 offers significant therapeutic potential for various cancer types.

Area of Science:

  • Molecular Biology
  • Oncology
  • RNA Biology

Background:

  • Insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) is an N6-methyladenosine reader regulating RNA stability and expression.
  • Aberrant IGF2BP2 expression is observed in numerous human cancers, influencing disease development and progression.
  • IGF2BP2 affects critical biological processes including proliferation, metastasis, chemoresistance, metabolism, tumor immunity, stemness, and cell death.

Purpose of the Study:

  • To summarize the clinical importance of IGF2BP2 in human cancers.
  • To discuss the multifaceted roles of IGF2BP2 in regulating cancer biology.
  • To review IGF2BP2 inhibitors and targeting microRNAs for cancer therapy.

Main Methods:

  • Literature review of studies on IGF2BP2 in human cancers.
  • Analysis of IGF2BP2's role in various cancer-related biological processes.
  • Compilation of information on IGF2BP2 inhibitors and targeting microRNAs.

Main Results:

  • IGF2BP2 plays significant roles in cancer proliferation, metastasis, chemoresistance, metabolism, immunity, stemness, and cell death.
  • Various chemical compounds have been developed as IGF2BP2 inhibitors.
  • Specific microRNAs directly target and inhibit IGF2BP2 expression in cancers.

Conclusions:

  • IGF2BP2 is clinically important and has great potential as a therapeutic target in human cancers.
  • Targeting IGF2BP2 through inhibitors or microRNAs presents promising avenues for cancer treatment.
  • Further research into IGF2BP2 may lead to novel therapeutic strategies for cancer.
Keywords:
IGF2BP2cancer progressionepitranscriptomic modificationm6A methylationtherapeutical implication

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.3K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K